Step 2 Semaglutide: Moving to 0.5 mg on Wegovy

Why does the schedule pause at 0.5 mg rather than moving straight to a higher dose?

The titration steps built into the Wegovy licence exist for a reason rooted in tolerability, not caution for its own sake. Semaglutide slows gastric emptying and reduces appetite by activating GLP-1 receptors — effects that are valuable for weight management but that the digestive system needs time to adjust to. Jumping straight to a maintenance-range dose would, for most people, produce a much rougher ride in the first weeks.

The 0.5 mg step sits between the introductory 0.25 mg and the next increment at 1.0 mg. It gives the body a second acclimatisation window. Some people find the nausea that accompanied the first step has largely settled by week five or six; others notice a modest uptick again after the increase. Both are normal patterns, and the NHS medicines page for semaglutide describes these GI effects as expected during titration.

The practical upshot: completing a full four weeks at 0.5 mg before moving on is not optional. Moving faster does not accelerate results, it increases the chance of side effects severe enough to require pausing treatment altogether, which would slow progress rather than speed it up.

What side effects are most likely at this point in the schedule?

The side-effect profile at 0.5 mg is broadly the same as at 0.25 mg, though some people find it more pronounced in the first week after the increase. Nausea is the most commonly reported effect, followed by constipation, loose stools, indigestion, and a general sense of fullness that arrives sooner during meals than before. Fatigue and mild headache are also reported, particularly in the first few days after a new dose.

Most of these settle. A useful checking habit: keep a brief note on your phone (just the day, your main symptom and its severity) for the first two weeks at each new dose level. A short log like that takes less than a minute each morning and gives your prescriber exactly the kind of pattern information that guides whether to stay at the current dose or continue to step 3 at 1.0 mg.

Symptoms that warrant prompt medical attention are different in character: severe, persistent abdominal pain that extends toward the back, signs of an allergic reaction, or symptoms of significant dehydration from repeated vomiting. The MHRA's Yellow Card scheme at yellowcard.mhra.gov.uk is the right place to report any suspected side effect, and doing so supports ongoing safety monitoring for everyone taking these medicines.

Does 0.5 mg produce meaningful weight loss, or is it still essentially a run-in dose?

The honest answer is that 0.5 mg is a transitional dose. The major weight-loss data for Wegovy comes from the 2.4 mg maintenance dose studied in the STEP 1 trial, which found an average body-weight reduction of around 15% over 68 weeks, a figure cited by NICE in their recommendation of semaglutide for weight management (TA875). That outcome is built over the full titration period, not just at maintenance.

People do begin to notice reduced appetite and some early weight change during the lower steps, including at 0.5 mg. Appetite suppression is present from the outset; the degree tends to increase as the dose rises. So 0.5 mg is doing something (it is not a placebo) but the full therapeutic effect accumulates over the entire schedule. Expecting dramatic results at this stage sets an unfair benchmark. Steady progress across all the steps is how the licensed treatment works. If you are also taking CBD and want to understand how it might interact with your treatment, our guidance on using CBD alongside Wegovy covers what is currently known and what to discuss with your prescriber.

If you are thinking about Wegovy as a treatment option and wondering whether the titration commitment is realistic for you, that is a good question to raise during a consultation. Our clinical team at nume reviews every patient's circumstances individually before recommending a treatment path.

What happens if 0.5 mg feels too much, can you stay at this dose or go back?

Yes. The titration schedule is a guide, not a strict timetable, and prescribers can slow it down or hold at a particular dose when that is clinically the right call. If side effects at 0.5 mg are significantly disrupting daily life, your prescriber may recommend staying at this step for longer than four weeks rather than progressing on schedule. In some cases, returning temporarily to 0.25 mg is considered.

What matters is that these decisions go through your prescriber rather than being made unilaterally. Adjusting doses independently, or sourcing additional pens to manage your own schedule, sits outside the safe framework the licence is built on. At nume, every repeat order is clinically reviewed (there is no auto-renewal) so if your experience at 0.5 mg raises questions, the repeat review is the moment to raise them. You can also reach us through our support team, available seven days a week.

If you are working out whether to start Wegovy through a regulated online pharmacy or have already begun and want to understand the full range of treatment options, speaking to a prescriber rather than navigating this alone is always the steadier approach.